Review

ccl5 levels (Boster Bio)

Boster Bio is a verified supplier

Boster Bio manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Boster Bio ccl5 levels

Palbociclib induces SASP-related <t>CCL5</t> in NSCLC cells. (a) The β -galactosidase staining in NSCLC cells induced by palbociclib. Left: images of β -Gal-stained H1650 and H226 cells with/without palbociclib. Scale bars represent 100 μ m. Right: the bar charts display the calculated numbers of β -Gal positive cells. (b) Protein expression levels of the genes involved in cell senescence after treatment with 2 μ M palbociclib. Left: gel images of western blot for genes' expression, with GAPDH as a loading control. Right: the bar charts display the relative expression of target genes on protein level. P16, P21, p-RB, and corresponding GAPDH were tested in the same experiment. And β -Gal, STING, and corresponding GAPDH were tested in another experiment. Western blot result of every target protein cropped from the same gel in the same experiment and the proteins with similar size came from different gels in the same experiment. (c) CCL5 mRNA expression levels in NSCLC cells treated with palbociclib of gradient concentration (left) and secreted CCL5 in the supernatants of NSCLC cell with 2 μ M palbociclib (right). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.

Ccl5 Levels, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccl5+levels/Human+CCL5%2FRANTES+Recombinant+Protein/pmc10175017-60-3-27
Average 92 stars, based on 20 article reviews

ccl5 levels - by Bioz Stars, 2026-09

92/100 stars

Images

1) Product Images from "Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer"

Article Title: Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer

Journal: Journal of Oncology

doi: 10.1155/2022/2260625

Palbociclib induces SASP-related CCL5 in NSCLC cells. (a) The β -galactosidase staining in NSCLC cells induced by palbociclib. Left: images of β -Gal-stained H1650 and H226 cells with/without palbociclib. Scale bars represent 100 μ m. Right: the bar charts display the calculated numbers of β -Gal positive cells. (b) Protein expression levels of the genes involved in cell senescence after treatment with 2 μ M palbociclib. Left: gel images of western blot for genes' expression, with GAPDH as a loading control. Right: the bar charts display the relative expression of target genes on protein level. P16, P21, p-RB, and corresponding GAPDH were tested in the same experiment. And β -Gal, STING, and corresponding GAPDH were tested in another experiment. Western blot result of every target protein cropped from the same gel in the same experiment and the proteins with similar size came from different gels in the same experiment. (c) CCL5 mRNA expression levels in NSCLC cells treated with palbociclib of gradient concentration (left) and secreted CCL5 in the supernatants of NSCLC cell with 2 μ M palbociclib (right). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.

Figure Legend Snippet: Palbociclib induces SASP-related CCL5 in NSCLC cells. (a) The β -galactosidase staining in NSCLC cells induced by palbociclib. Left: images of β -Gal-stained H1650 and H226 cells with/without palbociclib. Scale bars represent 100 μ m. Right: the bar charts display the calculated numbers of β -Gal positive cells. (b) Protein expression levels of the genes involved in cell senescence after treatment with 2 μ M palbociclib. Left: gel images of western blot for genes' expression, with GAPDH as a loading control. Right: the bar charts display the relative expression of target genes on protein level. P16, P21, p-RB, and corresponding GAPDH were tested in the same experiment. And β -Gal, STING, and corresponding GAPDH were tested in another experiment. Western blot result of every target protein cropped from the same gel in the same experiment and the proteins with similar size came from different gels in the same experiment. (c) CCL5 mRNA expression levels in NSCLC cells treated with palbociclib of gradient concentration (left) and secreted CCL5 in the supernatants of NSCLC cell with 2 μ M palbociclib (right). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.

Techniques Used: Staining, Expressing, Western Blot, Control, Concentration Assay

Blocking SASP-related CCL5 inhibits the migration ability induced by Palbociclib. (a) The effect of antagonists of CCR5 TAK-779 on the migration ability of NSCLC cells treated with 2 μ M Palbociclib. Upper: Images of migrated cell with Palbociclib or TAK-779, bar: 100 μ m. Lower: The results were analyzed using unpaired t -test. (b) Diagram showing how Palbociclib contributes to the migration and invasion of NSCLC via SASP-related CCL5.

Figure Legend Snippet: Blocking SASP-related CCL5 inhibits the migration ability induced by Palbociclib. (a) The effect of antagonists of CCR5 TAK-779 on the migration ability of NSCLC cells treated with 2 μ M Palbociclib. Upper: Images of migrated cell with Palbociclib or TAK-779, bar: 100 μ m. Lower: The results were analyzed using unpaired t -test. (b) Diagram showing how Palbociclib contributes to the migration and invasion of NSCLC via SASP-related CCL5.

Techniques Used: Blocking Assay, Migration

Image Search Results

Measurement of CCL5 and other markers related to bone metabolism and inflammation in the serum or urine obtained from all subjects. ( a ) Serum CCL5 levels are significantly higher in the group of all DJD-TMJ subjects (n = 17) than in control groups (n = 17). ( b ) Serum or urine markers related to bone metabolism and inflammation were compared between the control group (n = 17) and the group of all DJD-TMJ subjects (n = 17). t -test, two-tailed. * Indicates a significant difference at p < 0.05.

Journal: International Journal of Molecular Sciences

Article Title: Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females

doi: 10.3390/ijms24032775

Figure Lengend Snippet: Measurement of CCL5 and other markers related to bone metabolism and inflammation in the serum or urine obtained from all subjects. ( a ) Serum CCL5 levels are significantly higher in the group of all DJD-TMJ subjects (n = 17) than in control groups (n = 17). ( b ) Serum or urine markers related to bone metabolism and inflammation were compared between the control group (n = 17) and the group of all DJD-TMJ subjects (n = 17). t -test, two-tailed. * Indicates a significant difference at p < 0.05.

Article Snippet: CCL5 levels in serum were measured by an enzyme-linked linked immunosorbent assay (ELISA; Human CCL5 ELISA Kit, KE00093; Proteintech, IL, USA).

Techniques: Control, Two Tailed Test

List of laboratory results for all DJD-TMJ and control subjects. Highlighted in yellow shows patients with systemic diseases.

Journal: International Journal of Molecular Sciences

Article Title: Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females

doi: 10.3390/ijms24032775

Figure Lengend Snippet: List of laboratory results for all DJD-TMJ and control subjects. Highlighted in yellow shows patients with systemic diseases.

Article Snippet: CCL5 levels in serum were measured by an enzyme-linked linked immunosorbent assay (ELISA; Human CCL5 ELISA Kit, KE00093; Proteintech, IL, USA).

Techniques: Control

Measurement of CCL5 and other markers in the serum or urine obtained from subjects at ≤42 years old (Younger subjects). ( a ) Serum CCL5 levels are significantly higher in the group of DJD-TMJ subjects ≤42 years old (n = 10) than in the age-matched control groups (n = 11). ( b ) Serum or urine markers related to bone metabolism and inflammation were compared between the corresponding control groups (n = 11) and the group of DJD-TMJ subjects ≤ 42 years old (n = 10). t -test, two-tailed. * Indicates a significant difference at p < 0.05.

Journal: International Journal of Molecular Sciences

Article Title: Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females

doi: 10.3390/ijms24032775

Figure Lengend Snippet: Measurement of CCL5 and other markers in the serum or urine obtained from subjects at ≤42 years old (Younger subjects). ( a ) Serum CCL5 levels are significantly higher in the group of DJD-TMJ subjects ≤42 years old (n = 10) than in the age-matched control groups (n = 11). ( b ) Serum or urine markers related to bone metabolism and inflammation were compared between the corresponding control groups (n = 11) and the group of DJD-TMJ subjects ≤ 42 years old (n = 10). t -test, two-tailed. * Indicates a significant difference at p < 0.05.

Article Snippet: CCL5 levels in serum were measured by an enzyme-linked linked immunosorbent assay (ELISA; Human CCL5 ELISA Kit, KE00093; Proteintech, IL, USA).

Techniques: Control, Two Tailed Test

Measurement of CCL5 and other markers in the serum or urine obtained from subjects >42 years old (Older subjects). ( a ) Serum CCL5 levels are significantly higher in the group of DJD-TMJ subjects > 42 years old (n = 7) than in the age-matched control groups (n = 6). ( b ) Serum or urine markers related to bone metabolism and inflammation were compared between the corresponding control groups (n = 7) and the group of DJD-TMJ subjects >42 years old (n = 6). t -test, two-tailed. * indicates a significant difference at p < 0.05.

Journal: International Journal of Molecular Sciences

Article Title: Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females

doi: 10.3390/ijms24032775

Figure Lengend Snippet: Measurement of CCL5 and other markers in the serum or urine obtained from subjects >42 years old (Older subjects). ( a ) Serum CCL5 levels are significantly higher in the group of DJD-TMJ subjects > 42 years old (n = 7) than in the age-matched control groups (n = 6). ( b ) Serum or urine markers related to bone metabolism and inflammation were compared between the corresponding control groups (n = 7) and the group of DJD-TMJ subjects >42 years old (n = 6). t -test, two-tailed. * indicates a significant difference at p < 0.05.

Article Snippet: CCL5 levels in serum were measured by an enzyme-linked linked immunosorbent assay (ELISA; Human CCL5 ELISA Kit, KE00093; Proteintech, IL, USA).

Techniques: Control, Two Tailed Test

List of laboratory results for DJD-TMJ and control subjects at ≤42 years old (Younger subjects). Highlighted in yellow shows patients with systemic diseases.

Journal: International Journal of Molecular Sciences

Article Title: Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females

doi: 10.3390/ijms24032775

Figure Lengend Snippet: List of laboratory results for DJD-TMJ and control subjects at ≤42 years old (Younger subjects). Highlighted in yellow shows patients with systemic diseases.

Article Snippet: CCL5 levels in serum were measured by an enzyme-linked linked immunosorbent assay (ELISA; Human CCL5 ELISA Kit, KE00093; Proteintech, IL, USA).

Techniques: Control

The list of laboratory results for DJD-TMJ and control subjects at >42 years old (Older subjects). Highlighted in yellow shows patients with systemic diseases.

Journal: International Journal of Molecular Sciences

Article Title: Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females

doi: 10.3390/ijms24032775

Figure Lengend Snippet: The list of laboratory results for DJD-TMJ and control subjects at >42 years old (Older subjects). Highlighted in yellow shows patients with systemic diseases.

Article Snippet: CCL5 levels in serum were measured by an enzyme-linked linked immunosorbent assay (ELISA; Human CCL5 ELISA Kit, KE00093; Proteintech, IL, USA).

Techniques: Control

( a ) A principal component analysis of all control and DJD-TMJ subjects and ( b ) the measurement of serum CCL5 levels in an ovariectomized (OVX) rat model. ( a ) The principal component analysis showed that CCL5, bone metabolism markers, and TNF-α were independent. ( b ) Serum CCL5 levels in sham-operated, OVX and OVX-TPTD-treated rats did not differ significantly. Dunnett’s test.

Journal: International Journal of Molecular Sciences

Article Title: Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females

doi: 10.3390/ijms24032775

Figure Lengend Snippet: ( a ) A principal component analysis of all control and DJD-TMJ subjects and ( b ) the measurement of serum CCL5 levels in an ovariectomized (OVX) rat model. ( a ) The principal component analysis showed that CCL5, bone metabolism markers, and TNF-α were independent. ( b ) Serum CCL5 levels in sham-operated, OVX and OVX-TPTD-treated rats did not differ significantly. Dunnett’s test.

Article Snippet: CCL5 levels in serum were measured by an enzyme-linked linked immunosorbent assay (ELISA; Human CCL5 ELISA Kit, KE00093; Proteintech, IL, USA).

Techniques: Control

ROC curve analyses of CCL5. ROC curve analyses of CCL5 in ( a ) all DJD-TMJ patients (n = 17), ( b ) the group of all DJD-TMJ subjects ≤ 42 years old (n = 11), ( c ) the group of all DJD-TMJ subjects > 42 years old (n = 7) are shown.

Journal: International Journal of Molecular Sciences

Article Title: Association between an Increased Serum CCL5 Level and Pathophysiology of Degenerative Joint Disease in the Temporomandibular Joint in Females

doi: 10.3390/ijms24032775

Figure Lengend Snippet: ROC curve analyses of CCL5. ROC curve analyses of CCL5 in ( a ) all DJD-TMJ patients (n = 17), ( b ) the group of all DJD-TMJ subjects ≤ 42 years old (n = 11), ( c ) the group of all DJD-TMJ subjects > 42 years old (n = 7) are shown.

Article Snippet: CCL5 levels in serum were measured by an enzyme-linked linked immunosorbent assay (ELISA; Human CCL5 ELISA Kit, KE00093; Proteintech, IL, USA).

Techniques:

Fig. 3 CCL5 recruits fibroblasts through the CCR5 receptor. a Relative expression of CCR1, CCR3, CCR4, CCR5, CD44, GPR75 mRNA in CCD-18Co/ siCtrl and CCD-18Co/siRNA. Data, mean ± SD; n = 3. b Immunoblots for CCR1, CCR3, CCR4, CCR5, CD44, GPR75 protein expression in CCD-18Co/ siCtrl and CCD-18Co/siRNA. c Model diagram of recruitment assay of 40 ng/ml CCL5 to CCR1, CCR3, CCR4, CCR5, CD44, or GPR75 knockdown fibroblasts. d Recruitment assay showing the recruitment ability of 40 ng/ml CCL5 to CCD-18Co/siCtrl and CCD-18Co/siRNA. Scale bar, 100 μm. Quantification of cell numbers of recruited CCD-18Co cells is shown in the upper panel. Data, mean ± SD; n = 5. e Model diagram of recruitment assay of 40 ng/ml CCL5 to fibroblasts without or with CCR1 inhibitor (BX471) or CCR5 inhibitor (Maraviroc). f Recruitment assay showing the recruitment ability of 40 ng/ml CCL5 to CCD-18Co without or with BX471 or Maraviroc. Scale bar, 100 μm. Quantification of cell numbers of recruited CCD-18Co cells is shown in the left panel. Data, mean ± SD; n = 5. ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001 by two-tailed Student’s t test (a, d, f)

Journal: Journal of experimental & clinical cancer research : CR

Article Title: Tumor bud-derived CCL5 recruits fibroblasts and promotes colorectal cancer progression via CCR5-SLC25A24 signaling.

doi: 10.1186/s13046-022-02300-w

Figure Lengend Snippet: Fig. 3 CCL5 recruits fibroblasts through the CCR5 receptor. a Relative expression of CCR1, CCR3, CCR4, CCR5, CD44, GPR75 mRNA in CCD-18Co/ siCtrl and CCD-18Co/siRNA. Data, mean ± SD; n = 3. b Immunoblots for CCR1, CCR3, CCR4, CCR5, CD44, GPR75 protein expression in CCD-18Co/ siCtrl and CCD-18Co/siRNA. c Model diagram of recruitment assay of 40 ng/ml CCL5 to CCR1, CCR3, CCR4, CCR5, CD44, or GPR75 knockdown fibroblasts. d Recruitment assay showing the recruitment ability of 40 ng/ml CCL5 to CCD-18Co/siCtrl and CCD-18Co/siRNA. Scale bar, 100 μm. Quantification of cell numbers of recruited CCD-18Co cells is shown in the upper panel. Data, mean ± SD; n = 5. e Model diagram of recruitment assay of 40 ng/ml CCL5 to fibroblasts without or with CCR1 inhibitor (BX471) or CCR5 inhibitor (Maraviroc). f Recruitment assay showing the recruitment ability of 40 ng/ml CCL5 to CCD-18Co without or with BX471 or Maraviroc. Scale bar, 100 μm. Quantification of cell numbers of recruited CCD-18Co cells is shown in the left panel. Data, mean ± SD; n = 5. ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001 by two-tailed Student’s t test (a, d, f)

Article Snippet: CCL5 supernatant levels in the CM samples from FHC and human CRC tumor cells were measured with ELISA using a commercially available kit (CUSABIO, CSBE17375h), as described by the manufacturer’s instructions.

Techniques: Expressing, Western Blot, Knockdown, Two Tailed Test

Journal: Journal of Oncology

Article Title: Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer

doi: 10.1155/2022/2260625

Figure Lengend Snippet: Palbociclib induces SASP-related CCL5 in NSCLC cells. (a) The β -galactosidase staining in NSCLC cells induced by palbociclib. Left: images of β -Gal-stained H1650 and H226 cells with/without palbociclib. Scale bars represent 100 μ m. Right: the bar charts display the calculated numbers of β -Gal positive cells. (b) Protein expression levels of the genes involved in cell senescence after treatment with 2 μ M palbociclib. Left: gel images of western blot for genes' expression, with GAPDH as a loading control. Right: the bar charts display the relative expression of target genes on protein level. P16, P21, p-RB, and corresponding GAPDH were tested in the same experiment. And β -Gal, STING, and corresponding GAPDH were tested in another experiment. Western blot result of every target protein cropped from the same gel in the same experiment and the proteins with similar size came from different gels in the same experiment. (c) CCL5 mRNA expression levels in NSCLC cells treated with palbociclib of gradient concentration (left) and secreted CCL5 in the supernatants of NSCLC cell with 2 μ M palbociclib (right). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001.

Article Snippet: Thus, the secreted CCL5 levels in the media of palbociclib-treated cells and the control cells were assessed by enzyme-linked immunosorbent assay (ELISA) using CCL5 ELISA kit (EK0494, Boster Biological Technology, CA, USA) according to the manual instruction.

Techniques: Staining, Expressing, Western Blot, Control, Concentration Assay

Journal: Journal of Oncology

Article Title: Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer

doi: 10.1155/2022/2260625

Figure Lengend Snippet: Blocking SASP-related CCL5 inhibits the migration ability induced by Palbociclib. (a) The effect of antagonists of CCR5 TAK-779 on the migration ability of NSCLC cells treated with 2 μ M Palbociclib. Upper: Images of migrated cell with Palbociclib or TAK-779, bar: 100 μ m. Lower: The results were analyzed using unpaired t -test. (b) Diagram showing how Palbociclib contributes to the migration and invasion of NSCLC via SASP-related CCL5.

Techniques: Blocking Assay, Migration

Review

Structured Review

Images

1) Product Images from "Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer"

Similar Products

Image Search Results